Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q2 2024 · 10-Q
Revenue—
Net Income-$3.01M-$3.01MN/M vs Q2 2023 EPS Diluted-$1.01-$1.01N/M vs Q2 2023 Operating Income-$3,082,024N/M Operating Cash Flowderived-$3,345,829N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 13, 2024 · 44 d after period end